Matthew Potts1, Ben Myatt1, Sam Apoola2 & Peter Healey1
1Kindeva Drug Delivery Limited, Charnwood Campus, 10 Bakewell Road, Loughborough, LE11 5RB, United Kingdom
2School of Mechanical Engineering, Leeds University, Woodhouse Lane, Leeds, LS2 9JT, United Kingdom
Summary
Drug deposition in the mouth/throat is a common problem with many respirable medicines. To aid the development of products which reduce this deposition, suitable analytical methodology must be developed. Knowing more about where the drug is impacted within the mouth/throat can allow for greater insight into the causes of the deposition and what changes to the product may have the greatest impact on reducing this deposition. A split anatomical throat was designed, manufactured and then incorporated into analytical methodology developed to determine regional throat deposition and the fine particle mass/fraction (FPM/FPF). The methodology was developed utilising a Fast Screening Impactor (FSI) to achieve rapid screening of device prototypes and novel formulations.
Key Message
We developed novel anatomical throat apparatus and analytical methodology to accurately determine regional oropharyngeal drug deposition of inhaled respiratory medicines, enabling rapid screening of device prototypes and novel formulations. The drug deposition data is comparable to that generated using a standard OPC anatomical throat and Next Generation Impactor testing setup.